the proliferative4
effect of IL-3 on multipotential hematopoietic 1. Billiau, Immunol. Today, 8, 84 (1987).
progenitors.5
Performance Characteristics
This product is tested in mouse cells (T1165
determining optimal working dilutions by titration test.
References
1. Billiau, D., Immunol. Today, 8, 84 (1987).
2. Hirano, T., et al., Complementary DNA for a novel
human interleukin (BSF-2) that induces
result in loss of
activity.
REFERENCES 1. J Neurosci. 2004 Feb 25;24(8):1976-86.
2. Development. 2003 Feb;130(4):775-84.
3. Development. 2000 Mar;127(6):1231-41.
4. Neuron. 1994 May;12(5):957-75
, 10 mM
glutathione, 0.1 mM EDTA, 0.25 mM DTT, 0.1 mM
PMSF, and 25% glycerol.
Molecular mass: ∼84 kDa
Purity: 70–95% (SDS-PAGE, see Figure 1)
Specific Activity: 185–251 nmole/min/mg (see Figure
J. Neurosci., 17, 3599-3609
(1997).
8. Pesold, C., et al., Proc. Natl. Acad. Sci. USA, 96,
3217-3222 (1999).
9. Rice, D.S., et al., Development, 125, 3719-3729
(1998).
10. Bar, I., and
microscopic
colloidally stabilized phase in solubilizing
oligoamine-condensed DNA complexes. Biophys.
J., 84(2), 1124-1130 (2003).
12. Shui, X., et al., The B-DNA dodecamer at high
resolution reveals a spine
cDNA was synthesized using the Transcriptor First
Strand cDNA Synthesis Kit. Expression levels of 84
apoptosis-related genes were measured using the
RealTime ready Human Apoptosis Panel, 96. Analyzing
Piomelli S, Chen HC, Gross E: J. Lab
Clin Med 84:147 1974.
2. Corash LM: Density Dependent Red Cell
Separation. In Methods in Hematology, Vol 16, Chp
8, E. Beutler, Editor, Churchill-Livingstone Press